Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M321Revenue (TTM) $M162Net Margin (%)-126.5Altman Z-Score-45.5
Enterprise Value $M502EPS (TTM) $-0.6Operating Margin %-119.4Piotroski F-Score3
P/E(ttm)--Beneish M-Score4,128Pre-tax Margin (%)-126.5Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %-20.0Quick Ratio0.4Cash flow > EarningsY
Price/Sales2.05-y EBITDA Growth Rate %-14.6Current Ratio0.5Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-140.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M478ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with MNKD

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
MNKDFirst Eagle Investment 2013-03-31 Sold Out -0.0066%$2.31 - $3.56
$ 0.68-75%Sold Out0
MNKDFirst Eagle Investment 2012-12-31 Buy 0.01%$1.85 - $2.83
$ 0.68-69%New holding800,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MNKD is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

MNKD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PFEFFER MATTHEW JCEO, CFO, Director 2017-01-03Buy4,540$0.5424.07view
Alinaya Rosabel RealicaSVP, Prin Acctg Officer 2017-01-03Buy9,043$0.5424.07view
Castagna MichaelChief Commercial Officer 2016-08-26Buy17,500$0.78-14.1view
Castagna MichaelChief Commercial Officer 2016-08-24Buy15,000$0.87-22.99view
Castagna MichaelChief Commercial Officer 2016-08-23Buy25,000$0.94-28.72view
PFEFFER MATTHEW JCEO, CFO, Director 2016-08-15Buy25,000$0.99-32.32view
Castagna MichaelChief Commercial Officer 2016-08-12Buy25,000$1-33view
Alinaya Rosabel RealicaSVP, Prin Acctg Officer 2016-07-06Sell6,294$1.06-36.79view
Castagna MichaelChief Commercial Officer 2016-05-17Buy50,000$0.93-27.96view
Martens JuergenCorporate VP and COO 2015-05-21Buy20,000$4.57-85.34view

Press Releases about MNKD :

Quarterly/Annual Reports about MNKD:

News about MNKD:

Articles On GuruFocus.com
Why MannKind Could Be a Value Trap Jan 04 2016 
MannKind Corporation Disappoints with Afrezza Sales; Analysts Lower Expectations May 11 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 
Analysts Weigh in on MannKind Following Q4 Results Feb 27 2015 
What to Watch for: November 3-7 Nov 04 2014 
Roche to Acquire InterMune and Deliver Hope to Patients Worldwide Aug 25 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza Aug 15 2014 
There is a Tide in the Affairs of MannKind: When Taken At the Flood, Will Lead to Fortune Aug 14 2014 

More From Other Websites
Insulin Drug Offers Hope for MannKind Jan 12 2017
Biotech Short Sellers Run for Cover Jan 12 2017
MANNKIND CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Jan 12 2017
The 6 Most Shorted Nasdaq Stocks Jan 12 2017
MANNKIND CORP Files SEC form 8-K, Other Events Jan 10 2017
MannKind Receives $30.6 Million From Sanofi Jan 09 2017
CORRECTING AND REPLACING -- MannKind Corporation to Present at the J.P. Morgan 2017 Healthcare... Jan 05 2017
MannKind Corporation to Present at the J.P. Morgan 2017 Healthcare Conference Jan 05 2017
MannKind Announces Key Addition to Its Executive Management Ranks Jan 04 2017
MannKind Receives $1 Million Milestone From RLS Jan 03 2017
MannKind Receives $1 Million Milestone From RLS Jan 03 2017
Galena Biopharma Reveals Regulatory Pathway for GALE-401 Dec 29 2016
Zacks.com featured highlights: MannKind, Mirna Therapeutics, NextEra Energy, Sabre and Avinger Dec 29 2016
MannKind (MNKD) Shares March Higher, Can It Continue? Dec 29 2016
Biotech Short Interest Sinks Dec 28 2016
The 6 Most Shorted Nasdaq Stocks Dec 28 2016
Nate Pile's Top Recommendations For 2017 Dec 27 2016
2016 Was a Terrible Year for Biotech but the Tweets Were on Point Dec 22 2016
Alexion Soliris Fails in Phase II/III Delayed Graft Function Study Dec 22 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)